Detalles de la búsqueda
1.
Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA.4 and BA.5 in England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22279444
2.
Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22274483
3.
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22273281
4.
Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21266341
5.
Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257218
6.
Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22278987
7.
Interactions between SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test negative design
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20189647
8.
COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22272691
9.
Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22268896
10.
Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-19: national test-negative case-control study, England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21267408
11.
Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission - a prospective cohort study in England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21266401
12.
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21263583
13.
Characterising long COVID more than 6 months after acute infection in adults; prospective longitudinal cohort study, England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21253633
14.
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21252652
15.
Characteristics associated with COVID-19 vaccine uptake among adults in England (08 December to 17 May 2021)
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21262422
16.
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257658
17.
UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20179192
18.
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21267615
19.
Implementation and extended evaluation of the Euroimmun Anti-SARS-CoV-2 IgG assay and its contribution to the United Kingdom's COVID-19 public health response
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21265497
20.
Monitoring the COVID-19 immunisation programme through a National Immunisation Management System- Englands experience
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21263578